AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33593931 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple breath washout (MBW) using sulfur hexafluoride (SF6)
Number of subjects: 100
Study 33593931 — intervention group
Group type: COMPARATOR
Intervention: Age
Number of subjects: 100
Study 33593940 — intervention group
Group type: EXPERIMENTAL
Intervention: Agonist-antagonist myoneural interfaces (AMIs) below-knee amputation (AB)
Number of subjects: 22
Study 33593940 — intervention group
Group type: COMPARATOR
Intervention: Traditional below-knee amputation (TB)
Number of subjects: 22
Study 33593994 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulants (OAC)
Number of subjects: 25551
Study 33593994 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-vitamin K antagonist oral anticoagulants (NOAC)
Number of subjects: 25551
Study 33593994 — intervention group
Group type: COMPARATOR
Intervention: NOAC
Number of subjects: 25551
Study 33594075 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant anti-OX40 (MEDI6469) therapy
Number of subjects: 17
Study 33594224 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracellular vesicle GFAP concentrations in TBI patients
Number of subjects: 72
Study 33594224 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracellular vesicle NfL concentrations in TBI patients
Number of subjects: 72
Study 33594224 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 subjects)
Number of subjects: 72
Study 33594451 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical Thrombectomy (MT)
Number of subjects: 307
Study 33594451 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-MT Parenchymal Hematoma (PH)
Number of subjects: 307
Study 33594489 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with cVFs (T7-T8 and T11-T12)
Number of subjects: 1237
Study 33594489 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with lcVFs (T4-T6 and T9-T10)
Number of subjects: 1237
Study 33594489 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with both cVFs and lcVFs
Number of subjects: 1237
Study 33594489 — intervention group
Group type: COMPARATOR
Intervention: Subjects without VFs
Number of subjects: 1237
Study 33594602 — intervention group
Group type: EXPERIMENTAL
Intervention: CRLX301 at 75 mg/m2 Q3W
Number of subjects: 42
Study 33594602 — intervention group
Group type: EXPERIMENTAL
Intervention: CRLX301
Number of subjects: 42
Study 33594934 — intervention group
Group type: EXPERIMENTAL
Intervention: Current practices and challenges in anal cancer screening for WLWH
Number of subjects: 25
Study 33595110 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33595155 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT-1004-1239 (10-100 mg/kg, twice daily, orally)
Number of subjects: 0
Study 33595155 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT-1004-1239 (100 mg/kg, twice daily)
Number of subjects: 0
Study 33595155 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT-1004-1239
Number of subjects: 0
Study 33595690 — intervention group
Group type: EXPERIMENTAL
Intervention: Trilaciclib at a dose of 240 mg/m
Number of subjects: 0
Study 33595690 — intervention group
Group type: EXPERIMENTAL
Intervention: Trilaciclib at a dose of ≥192 mg/m
Number of subjects: 0
Study 33595733 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation
Number of subjects: 501
Study 33595793 — intervention group
Group type: EXPERIMENTAL
Intervention: PEGylated Asparaginase (PEG-ASNase) 2500 U/m2
Number of subjects: 1374
Study 33595793 — intervention group
Group type: EXPERIMENTAL
Intervention: PopPK model
Number of subjects: 1374
Study 33595899 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal dietary diversity score (DDS) in the highest quartile (diverse diets)
Number of subjects: 3291
Study 33595899 — intervention group
Group type: COMPARATOR
Intervention: Maternal dietary diversity score (DDS) in Quartile 1 (low dietary diversity)
Number of subjects: 3291
Study 33596152 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and exercise habits (assessed with Healthy Eating Vital Signs and Stanford Brief Activity Survey)
Number of subjects: 129
Study 33596152 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear modelling
Number of subjects: 129
Study 33596161 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk obstructive sleep apnea treatment
Number of subjects: 0
Study 33596161 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 33596309 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting plasma GLP-1 concentrations in the obesity clinic group (median 3.3 pmol/L; interquartile range, 2.3-4.3 pmol/L)
Number of subjects: 1978
Study 33596309 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting GLP-1 concentrations
Number of subjects: 1978
Study 33596668 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 viremia (detected in plasma from 48 (39%) patients at baseline)
Number of subjects: 123
Study 33596668 — intervention group
Group type: COMPARATOR
Intervention: Patients without viremia
Number of subjects: 123
Study 33596867 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (IVT-AFL)
Number of subjects: 225
Study 33596889 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 pandemic impact assessment
Number of subjects: 0
Study 33596889 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 epidemiology and public health measures
Number of subjects: 0
Study 33596889 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological distress assessment
Number of subjects: 0
Study 33596889 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression assessment
Number of subjects: 0
Study 33596889 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety assessment
Number of subjects: 0
Study 33596889 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-traumatic stress symptoms assessment
Number of subjects: 0
Study 33597012 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss
Number of subjects: 2743
Study 33597012 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight change
Number of subjects: 2743
Study 33597041 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice facilitation (PF) strategy
Number of subjects: 10
Study 33597130 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment instruments used in the review
Number of subjects: 68
Study 33597145 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes
Number of subjects: 11846
Study 33597145 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 11846
Study 33597145 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 11846
Study 33597145 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic kidney disease
Number of subjects: 11846
Study 33597145 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes (younger subgroup)
Number of subjects: 11846
Study 33597145 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes (women)
Number of subjects: 11846
Study 33597145 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes (non-EU immigrants)
Number of subjects: 11846
Study 33597152 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucocorticoid therapy, immunotherapies, and biologic therapy
Number of subjects: 18829
Study 33597152 — intervention group
Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 18829
Study 33597152 — intervention group
Group type: EXPERIMENTAL
Intervention: People with IBD
Number of subjects: 18829
Study 33597152 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild lymphopenia and neutropenia in people with IBD
Number of subjects: 18829
Study 33597152 — intervention group
Group type: COMPARATOR
Intervention: Mild lymphopenia and neutropenia in controls
Number of subjects: 18829
Study 33597215 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate- to vigorous-intensity physical activity (MVPA)
Number of subjects: 0
Study 33597215 — intervention group
Group type: EXPERIMENTAL
Intervention: Timing of bout-related MVPA
Number of subjects: 0
Study 33598307 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive telemedicine
Number of subjects: 0
Study 33598307 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 0
Study 33598309 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecological momentary assessment (EMA) and wrist-worn ActiGraph Link
Number of subjects: 40
Study 33598309 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour dietary recalls via structured interview
Number of subjects: 40
Study 33598473 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Fasting
Number of subjects: 0
Study 33598473 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 33598475 — intervention group
Group type: EXPERIMENTAL
Intervention: Saffron extract (30 mg standardized saffron extract for 8 weeks)
Number of subjects: 56
Study 33598475 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 33598552 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure lowering treatment (target <140 mmHg <1 h)
Number of subjects: 3233
Study 33598552 — intervention group
Group type: COMPARATOR
Intervention: Guideline-recommended blood pressure lowering treatment (<180 mmHg)
Number of subjects: 3233
Study 33598562 — intervention group
Group type: EXPERIMENTAL
Intervention: Thin slice computed tomography perfusion (CTP) images and cardiac computed tomography techniques
Number of subjects: 0
Study 33598562 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed tomography-derived predictors
Number of subjects: 0
Study 33598562 — intervention group
Group type: COMPARATOR
Intervention: Post-processed thin-slice CTP images
Number of subjects: 0
Study 33598562 — intervention group
Group type: COMPARATOR
Intervention: Imaging findings
Number of subjects: 0
Study 33598844 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass
Number of subjects: 51
Study 33598844 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (group A: one oral hypoglycemic agent)
Number of subjects: 51
Study 33598865 — intervention group
Group type: EXPERIMENTAL
Intervention: Active sacroiliitis on MRI
Number of subjects: 251
Study 33598865 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-TNF-α treatments
Number of subjects: 251
Study 33598865 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram prediction model
Number of subjects: 251
Study 33598865 — intervention group
Group type: COMPARATOR
Intervention: Clinical experience model
Number of subjects: 251
Study 33598905 — intervention group
Group type: EXPERIMENTAL
Intervention: CHICA-SUDEP module implementation
Number of subjects: 101
Study 33598905 — intervention group
Group type: COMPARATOR
Intervention: Before implementation
Number of subjects: 101
Study 33598905 — intervention group
Group type: EXPERIMENTAL
Intervention: After implementation
Number of subjects: 101
Study 33598942 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendamustine (30, 40, or 60 mg/m²) in combination with clofarabine, etoposide, and dexamethasone for 5 days
Number of subjects: 16
Study 33598942 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendamustine (substituted for cyclophosphamide) in combination with clofarabine and etoposide
Number of subjects: 16
Study 33598954 — intervention group
Group type: COMPARATOR
Intervention: No risk factors in men
Number of subjects: 30446
Study 33598954 — intervention group
Group type: EXPERIMENTAL
Intervention: Six or more risk factors in men
Number of subjects: 30446
Study 33598954 — intervention group
Group type: COMPARATOR
Intervention: No risk factors in women
Number of subjects: 30446
Study 33598954 — intervention group
Group type: EXPERIMENTAL
Intervention: Six or more risk factors in women
Number of subjects: 30446
Study 33599146 — intervention group
Group type: EXPERIMENTAL
Intervention: Agalsidase beta
Number of subjects: 396
Study 33599463 — intervention group
Group type: EXPERIMENTAL
Intervention: All-suture anchor dynamic anterior stabilization
Number of subjects: 3
Study 33599735 — intervention group
Group type: EXPERIMENTAL
Intervention: Foveal pit depth and inner retinal layer (IRL) thickness measurements in extremely premature infants
Number of subjects: 102
Study 33599735 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of foveal pit depth and IRL thickness over time
Number of subjects: 102
Study 33599735 — intervention group
Group type: EXPERIMENTAL
Intervention: Developmental displacement of the IRL
Number of subjects: 102
Study 33599800 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes patients hospitalised for COVID-19
Number of subjects: 2796
Study 33599941 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein plant-based diet (~ 1.6 g kg)
Number of subjects: 19
Study 33599941 — intervention group
Group type: COMPARATOR
Intervention: Protein-matched omnivorous diet
Number of subjects: 19
Study 33599951 — intervention group
Group type: EXPERIMENTAL
Intervention: UUI patients
Number of subjects: 10
Study 33600102 — intervention group
Group type: EXPERIMENTAL
Intervention: Intestinal mucosal samples from patients with FA
Number of subjects: 0
Study 33600102 — intervention group
Group type: EXPERIMENTAL
Intervention: Intestinal mucosal samples from patients with FH
Number of subjects: 0
Study 33600102 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study 33600102 — intervention group
Group type: EXPERIMENTAL
Intervention: Intestinal mucosal samples for IgE antibody determination
Number of subjects: 0
Study 33600102 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of diagnostic methods
Number of subjects: 0
Study 33600137 — intervention group
Group type: COMPARATOR
Intervention: Standard bleeding control course
Number of subjects: 66
Study 33600137 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleeding control course with addition of simulation and feedback device
Number of subjects: 66
Study 33600137 — intervention group
Group type: EXPERIMENTAL
Intervention: Retention testing 2 to 8 months later
Number of subjects: 66
Study 33600210 — intervention group
Group type: EXPERIMENTAL
Intervention: Eprenetapopt plus Azacitidine (AZA)
Number of subjects: 52
Study 33600745 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumacaftor-Ivacaftor
Number of subjects: 0
Study 33600745 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 33601050 — intervention group
Group type: EXPERIMENTAL
Intervention: Step count
Number of subjects: 0
Study 33601057 — intervention group
Group type: EXPERIMENTAL
Intervention: AAV8-RS1 gene therapy
Number of subjects: 11
Study 33601057 — intervention group
Group type: COMPARATOR
Intervention: Healthy male controls
Number of subjects: 11
Study 33601960 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography
Number of subjects: 0
Study 33601960 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 33602206 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical decision-support system (CDSS) for SIRS detection
Number of subjects: 168
Study 33602206 — intervention group
Group type: COMPARATOR
Intervention: Physicians' SIRS recognition during clinical routine
Number of subjects: 168
Study 33602254 — intervention group
Group type: EXPERIMENTAL
Intervention: FOPR test for HSN+SS
Number of subjects: 63
Study 33602254 — intervention group
Group type: EXPERIMENTAL
Intervention: FOPR test for HSN-SS
Number of subjects: 63
Study 33602254 — intervention group
Group type: EXPERIMENTAL
Intervention: FOPR test for healthy controls
Number of subjects: 63
Study 33602254 — intervention group
Group type: COMPARATOR
Intervention: FOPR test
Number of subjects: 63
Study 33602286 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular injection of umbilical cord-derived Wharton's Jelly (UC-derived WJ)
Number of subjects: 12
Study 33602313 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A injections
Number of subjects: 30
Study 33602316 — intervention group
Group type: EXPERIMENTAL
Intervention: Belinostat (1000 mg/m2) combined with CHOP (Bel-CHOP)
Number of subjects: 23
Study 33602316 — intervention group
Group type: EXPERIMENTAL
Intervention: Belinostat (1000 mg/m2) on Day 1-3 schedule
Number of subjects: 23
Study 33602316 — intervention group
Group type: EXPERIMENTAL
Intervention: Belinostat (1000 mg/m2) on Day 1-5 schedule
Number of subjects: 23
Study 33602338 — intervention group
Group type: EXPERIMENTAL
Intervention: ABLE 1.0 intervention (8-week program)
Number of subjects: 30
Study 33602357 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard infant formula (SF)
Number of subjects: 141
Study 33602357 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental infant formula (EF)
Number of subjects: 141
Study 33602357 — intervention group
Group type: COMPARATOR
Intervention: Breastfeeding (BF)
Number of subjects: 141
Study 33602357 — intervention group
Group type: COMPARATOR
Intervention: Formula fed groups (SF and EF)
Number of subjects: 141
Study 33602357 — intervention group
Group type: COMPARATOR
Intervention: Infant formula groups (SF and EF)
Number of subjects: 141
Study 33602654 — intervention group
Group type: EXPERIMENTAL
Intervention: PSMA PET/CT
Number of subjects: 213
Study 33602654 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram for predicting overall upstaging
Number of subjects: 213
Study 33602696 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexatherapy regimen composed of adenovirus-based vaccine, IL-15 superagonist (N-803), anti-OX40, anti-4-1BB, anti-PD-L1, and docetaxel.
Number of subjects: 2
Study 33602702 — intervention group
Group type: EXPERIMENTAL
Intervention: Sepsis Fast Track (SFT) programme
Number of subjects: 3806
Study 33602702 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (non-exposed group)
Number of subjects: 3806
Study 33602926 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard TB therapy
Number of subjects: 110
Study 33602926 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental TB treatment (did not reduce Mtb bacterial load)
Number of subjects: 110
Study 33602926 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 110
Study 33603385 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital medicine system (DMS)
Number of subjects: 44
Study 33603496 — intervention group
Group type: EXPERIMENTAL
Intervention: Water vapor endometrial ablation
Number of subjects: 155
Study 33603701 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare professionals (HCPs)
Number of subjects: 1050
Study 33603701 — intervention group
Group type: COMPARATOR
Intervention: Non-healthcare professionals (controls)
Number of subjects: 1050
Study 33603701 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up questionnaires at 6 weeks and 4 months
Number of subjects: 1050
Study 33603701 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical wellbeing assessment
Number of subjects: 1050
Study 33603701 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable provision of personal protection equipment
Number of subjects: 1050
Study 33603710 — intervention group
Group type: EXPERIMENTAL
Intervention: Perturbation-Based Balance Training
Number of subjects: 0
Study 33603710 — intervention group
Group type: COMPARATOR
Intervention: Conventional Intensive Balance Training
Number of subjects: 0
Study 33604351 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant-Based Diets
Number of subjects: 0
Study 33604351 — intervention group
Group type: COMPARATOR
Intervention: Animal-Based Diets
Number of subjects: 0
Study 33604400 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent COVID-19 plasma (CCP) treatment
Number of subjects: 94
Study 33604400 — intervention group
Group type: COMPARATOR
Intervention: Matched control group (no CCP available)
Number of subjects: 94
Study 33604458 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent paclitaxel-based chemoradiotherapy (CRT)
Number of subjects: 57
Study 33604458 — intervention group
Group type: COMPARATOR
Intervention: Other modalities (Non-CRT)
Number of subjects: 57
Study 33604486 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth education program with tutor support (n = 178)
Number of subjects: 326
Study 33604486 — intervention group
Group type: COMPARATOR
Intervention: Telehealth education program without tutor support (Control group not explicitly mentioned)
Number of subjects: 326
Study 33604802 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnoea (OSA) group
Number of subjects: 280
Study 33604802 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 280
Study 33604947 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatitis Activity Scoring System (PASS)
Number of subjects: 434
Study 33604947 — intervention group
Group type: EXPERIMENTAL
Intervention: PASS trajectories in mild AP
Number of subjects: 434
Study 33604947 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine equivalent dose
Number of subjects: 434
Study 33604999 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating tumor cell (CTC) enumeration and expression of PD-L1 and HLA-I
Number of subjects: 0
Study 33604999 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal evaluation of CTC enumeration
Number of subjects: 0
Study 33605440 — intervention group
Group type: COMPARATOR
Intervention: Behavioural support provided by dental professionals (one session)
Number of subjects: 14897
Study 33605440 — intervention group
Group type: COMPARATOR
Intervention: Behavioural support combined with pharmacotherapy (e.g., nicotine replacement therapy or e-cigarettes)
Number of subjects: 14897
Study 33605440 — intervention group
Group type: COMPARATOR
Intervention: Usual care, brief advice, very brief advice, or less active treatment
Number of subjects: 14897
Study 33605445 — intervention group
Group type: EXPERIMENTAL
Intervention: Obinutuzumab (GA101; G) alone (G-mono)
Number of subjects: 971
Study 33605445 — intervention group
Group type: EXPERIMENTAL
Intervention: Obinutuzumab (G) with fludarabine and cyclophosphamide (G-FC)
Number of subjects: 971
Study 33605445 — intervention group
Group type: EXPERIMENTAL
Intervention: Obinutuzumab (G) with bendamustine (G-bendamustine)
Number of subjects: 971
Study 33605465 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment (AHT) including β-blockers and/or ACE inhibitors
Number of subjects: 1425
Study 33605465 — intervention group
Group type: COMPARATOR
Intervention: No antihypertensive treatment (Control)
Number of subjects: 1425
Study 33605465 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with VIT treatment failure
Number of subjects: 1425
Study 33605481 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 407